The Biodesign Dural Graft is intended for use as a dura substitute for repairing dura mater.
Nexsis Biosciences is the exclusive U.S. and Canadian provider of Sales Support for the Cook Biotech Biodesign Dural Graft
ORDER NUMBER | REFERENCE PART NO. | INSTRUCTIONS FOR USE | SIZE (CM) |
---|---|---|---|
G31090 | C-DUR-4x7 | Learn More | 4 x 7 |
G32437 | C-DUR-2x3 | Learn More | 2 x 3 |
G31091 | C-DUR-7x10 | Learn More | 7 x 10 |
G31092 | C-DUR-7x20 | Learn More | 7 x 20 |
Order No: G31090
Reference Part No: C-DUR-4×7
Instructions for Use
Size (cm): 4 x 7
Order No: G32437
Reference Part No: C-DUR-2×3
Instructions for Use
Size (cm): 2 x 3
Biodesign biologic grafts are derived from small intestinal submucosa (SIS), a naturally occurring, intact extracellular matrix. SIS acts as a scaffold that allows host cells to infiltrate and remodel into vascularized tissue, leaving no permanent material in the patient’s body.
Bejjani GK, Zabramski J; Durasis Study Group. Safety and efficienty of porcine small intestine small mucosa dural subsititute: results of a prospective multicenter study and literature review. J Neurosurg. 2007; 106(6):1028-1033
Purpose: The purpose of this study was to assess the real-world performance of the Biodesign graft as a dura substitute for repairing dura mater. This report specifically analyzes a subset of patients who underwent trans-cranial dura mater repairs with the Biodesign graft.
Endpoints: The primary endpoint was the postoperative integrity of the graft 1 month after surgery as defined by the lack of need to return to the operating room to repair a cerebrospinal fluid (CSF) leak. Secondary endpoints included postoperative graft integrity at the last available patient follow-up visit (with a minimum of 6 months’ follow-up) and the assessment of adverse events for normal, widespread use of the graft in the short-term postoperative period. Data were collected from 81 patients at Toronto Western Hospital, Toronto, Ontario, Canada.
Results: Eighty-one patients were included in the final analysis.
SIS acts as a scaffold material to support the population of the ECM with patient-derived cells
SIS is gradually replaced by the patient’s own tissue and cells
The patient’s own collagen gradually matures into a stable structure that has long-term strength but is entirely the patient’s own